Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new book is published this week by Oxford University Press written by Associate Professor John Parrington. ‘Mind Shift’ draws on new scientific evidence to offer a substantive material explanation of self-conscious awareness in humans.

MindShift The book also provides major new insights into the biological and social roots of mental disorders, considers why human consciousness is unique compared to that of other species and poses important questions about how humanity can use new awareness about human consciousness to develop a truly sustainable civilisation.

Commenting on the new book, David Eagleman, neuroscientist at Stanford and NYT best-selling author of Livewired and The Runaway Species, stated: “What is it about the human brain that allowed it to take over every corner of the planet? And what does that have to do with language, culture, art, and consciousness? With a keen and insightful eye, Parrington dissects what we know about the mind and rebuilds it into a powerful framework.”

Details: https://global.oup.com/academic/product/mind-shift-9780198801634?cc=gb&lang=en

 

Similar stories

EMA approval of IntraBio’s Aqneursa marks a major milestone for the Department of Pharmacology, with further Phase 3 success in Ataxia Telangiectasia

On 21 January, the European Medicines Agency (EMA) approved Aqneursa, a new treatment for Niemann-Pick Disease Type C (NPC) in adults and children, marking a major milestone for research originating in the Department of Pharmacology. Aqneursa already received US FDA approval (September 2024), enabling patient access on both sides of the Atlantic.